Loading stock data…
$5.83-0.05 (-0.85%)
Evommune, Inc.
EVMN in the Healthcare sector is trading at $5.83 with a market capitalization of $340M. Wall Street consensus targets $22.33 (9 analysts), implying a +283.1% move over the next 12 months. The stock is currently near its 52-week low of $5.69, remaining 68.5% below its 200-day moving average. On fundamentals, Piotroski 0/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 6 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $10.00M | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.90M↓ | -$23.95M↑ | -$29.72M↓ | -$13.33M | — |
| Net Income | -$32.25M↓ | -$21.67M↑ | -$28.27M↓ | -$12.47M | — |
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneou...